Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

B – Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL…
posteditor
posteditor
Articles: 21727

Other News